Humacyte

OverviewSuggest Edit

Humacyte is a regenerative medical technology company focused on the development of human acellular matrix products for vascular and non-vascular applications. It uses its proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues.
TypePrivate
Founded2004
HQDurham, NC, US
Websitehumacyte.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Sept 2021)122
Cybersecurity ratingBMore

Key People/Management at Humacyte

Douglas L. Blankenship

Douglas L. Blankenship

Chief Financial Officer
Laura E. Niklason

Laura E. Niklason

Founder, President & Chief Executive Officer, Director
Jeffrey H

Jeffrey H

Chief Surgical Officer
Heather Prichard

Heather Prichard

Chief Operating Officer
William Tente

William Tente

Chief Regulatory Officer
Scott Weit

Scott Weit

Vice President of Quality
Show more

Humacyte Office Locations

Humacyte has an office in Durham
Show all (1)

Humacyte Financials and Metrics

Summary Metrics

Founding Date

2004

Humacyte total Funding

$187.3 m

Humacyte latest funding size

$150 m

Time since last funding

3 years ago

Humacyte investors

Humacyte's latest funding round in June 2018 was reported to be $150 m. In total, Humacyte has raised $187.3 m
Show all financial metrics

Humacyte Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Humacyte Online and Social Media Presence

Embed Graph

Humacyte News and Updates

Fresenius Medical Care increases investment in Humacyte, accompanies human acellular vessel developer's stock market launch

WALTHAM, Mass., Aug. 30, 2021 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, is investing an additional USD 25 million in the U.S. medical company Humacyte, Inc. In connection with the merger of Humacyte...

Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the successful completion of its business combination (the “Business Combination”) with…

Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels

DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioe…

Humacyte Announces Addition of Chief Commercial Officer and Integration of Commercial-Scale Manufacturing into Clinical Trial Programs

DURHAM, N.C., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced advancements in its commercial operations with the appointment of B.J. Scheessele as Ch…

Alpha Healthcare and Humacyte Announce Nominees for Election to Post-Merger Public Company Board of Directors

NEW YORK and DURHAM, N.C., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced the nominees who will stand for election/reelection to its Board of Directors during the August 24, 2021, AHAC special sha…

Humacyte Announces Publication of In Vivo Data on Biovascular Pancreas Transplantation for the Treatment of Type 1 Diabetes

DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced laboratory and preclinical data demonstrating the potential to engineer a biovascular pancrea…
Show more

Humacyte Frequently Asked Questions

  • When was Humacyte founded?

    Humacyte was founded in 2004.

  • Who are Humacyte key executives?

    Humacyte's key executives are Douglas L. Blankenship, Laura E. Niklason and Jeffrey H.

  • How many employees does Humacyte have?

    Humacyte has 122 employees.

  • Who are Humacyte competitors?

    Competitors of Humacyte include Tevosol, Gel4Med and Spiderwort.

  • Where are Humacyte offices?

    Humacyte has an office in Durham.

  • How many offices does Humacyte have?

    Humacyte has 1 office.